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Abstract – Objective: Liver cancer is the sixth common cancer and the second leading cause 
of death from cancer around the world. It is significantly more observable among male with its 
highest incidence in the age group of 45 to 60 years. The aim of this study was to investigate the 
incidence, mortality, and risk factors of liver cancer in the world. 
Materials and Methods: This review study was performed on published English studies by 
searching for databases PubMed, Scopus and web of science up to end of 2017. The strategy search 
includes key words of “Liver cancer”, “Hepatocellular carcinoma (HCC)”, “Epidemiology”, “inci-
dence”, “mortality”, “risk Factors”, and “the world”. We reviewed studies on the incidence, mor-
tality, and risk factors of liver cancer. 
Results: Generally, liver cancer is more common in the East Asia with, the highest incidence 
rate in Mongolia. The standard incidence of liver cancer was 10.1 per 100,000 people (15.3 in males 
and 5.3 in females). The highest mortality rates occurred observed in the East Asian countries. The 
standardized mortality rate for liver cancer was 9.5 per 100,000 people (14.3 in males and 5.1 in 
females). The most important risk factors for liver cancer included the chronic infections with HBV 
and HCV, Aflatoxin, alcohol consumption and cigarette smoking. 
Conclusions: Liver cancer has a higher incidence rate in East Asian countries. Majority of the 
cases are detected mostly at the advanced level of disease. Then, an early diagnosis could be ef-
fective in reducing mortality rate of this cancer. Also, conparing HCV(hepatitis C virus)   and HIV 
(human immunodeficiency virus) may lead to reducing risk factors of liver cancer. 
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INCIDENCE RATE
In total, there were 782,451 cases of LC world-
wide in 2012. Among this, 554369 cases occurred 
in males and 228082 in females. The Age-Stan-
dardized Incidence Rate (ASIR) of LC was 10.1 
(in males were15.3 and in females were 5.3). Based 
on the continental division, the highest and lowest 
ASIR of LC was 20.9 and 3.1 for Eastern Asia and 
Northern Europe respectively14. 
The highest and lowest ASIR worldwide were 
78.1 and 0.9 in Mongolia and Nepal, respectively. 
In Mongolia, LC with 6408 cases in 2003-2007, was 
reported as the most common cancer in both men 
and women15. However, more than a half of new 
cases and deaths from LC occur in China16; and a 
major portion of this rising in cancer burden can 
be attributed to population growth, aging and so-
cio-demographic changes17. South Korea is another 
country with a high incidence of LC. In this coun-
try, the incidence of LC was soaring from 1999 to 
2011, while declined during the period  from 2011 to 
2014, probably due to the significant advances in the 
treatment of viral hepatitis, despite the fact that the 
obesity and uncontrolled liver disease were also the 
main causes of LC18. In general, the global trend for 
the incidence of this cancer is widely variable in the 
world. For instance, despite the reducing incidence 
of LC in China, Philippines and Singapore, its inci-
dence was increasing in the United States, Britain, 
Canada, Australia, Germany and Switzerland19. The 
geographical model for incidence of this cancer is 
dependent on etiological viral factors20
MORTALITY RATE
In 2012, there were 745,533 deaths from LC of which 
52,104 (69.89%) were in males and 224,492 cases 
(30.11%) in females worldwide and the Age-Stan-
dardized Mortality Rate (ASMR) for LC was 9.5 
(in males were 14.3 and in females were 5.1). Based 
on the continental division, the highest and lowest 
ASMR of LC were 19.6 and 2.8 for Eastern Asia and 
Northern Europe14. 
In general, the mortality from LC has decreased 
in countries with previously high mortality rates 
and increased in areas with the previous low mortal-
ity in recent years21. In South Korea, the survival of 
LC has increased over the past two decades, so that 
five-year survival rate of LC increased from 10.7% 
in the period of between 1993 and 1995 to 32.8 in 
2010-201418. While the death from more types of 
cancer dropped sharply in the United States, the 
mortality rate from LC had a growing trend from 
2003 to 2012 with the highest mortality rate among 
male patients in the United States in 201222,23. Such 
INTRODUCTION 
Cancers are the main cause of mortality and health 
problem worldwide, and liver cancer (LC) is one of 
the most common1-3. It is considered as the sixth most 
common cancer and the second leading cause of can-
cer deaths around the world4. Liver cancer is divid-
ed into two types: primary and secondary LC. The 
primary LC starts in the liver, but the secondary LC 
begins in other organs of the body and spreads to the 
liver due to metastases of this cancer and creation of 
the most common cases including colorectal, breast, 
pancreatic, ovarian and lung cancers5. Primary liver 
tumors include Hepatocellular carcinoma, Cholangio 
carcinoma and Sarcoma which account for about 6% 
of the total cancer burden worldwide6. 
The incidence of primary LC is very diverse in 
different countries7. The highest incidence of this 
cancer can be seen in Eastern Asia, South-Eastern 
Asia, Northern Africa and Southern Africa8. In gen-
eral, it has a high incidence in developing countries 
so that more than 85% of cases occur in these coun-
tries9. This cancer is significantly more common in 
men10. This difference is higher in regions with high 
incidence than areas with lower one11. The highest 
incidence of LC occurs in the age group of 45-60 
years12, and its treatment may be difficult because 
most cases, especially in developing countries, are 
diagnosed in advanced grade and does not poten-
tially respond to drug therapy13. 
According to previous studies, there are widely 
various differences in estimating mortality and inci-
dence rate of LC around the world yearly. It is true 
that multiple risk factors may lead to LC; however, 
there is no comprehensive literature about the inci-
dence, mortality, and risk factors of LC. Turning to 
the fact that epidemiological aspects recognition and 
incidence and mortality awareness of this cancer 
may lead to diminish severity and incidence of LC, 
the aim of this study was to investigate the incidence, 
mortality, and risk factors of liver cancer in the world.
MATERIALS AND METHODS
This investigation was performed on published En-
glish studies by searching on PubMed, Scopus and 
web of science up to end of 2017. The search strategy 
included key words “Liver cancer”, “Hepatocellular 
carcinoma (HCC)”, “Epidemiology”, “incidence”, 
“mortality” and “risk factors”. We investigated the 
relevant studies on the incidence, mortality and risk 
factors of LC. which addressed the therapeutic and 
surgical aspects of liver cancer were excluded. A to-
tal of 90 full papers were reviewed. In this study, 
the incidence and mortality rates are considered per 
100,000 people at risk of disease.
3LIVER CANCER IN THE WORLD: EPIDEMIOLOGY, INCIDENCE, MORTALITY AND RISK FACTORS
the model of relationship between smoking and the 
risk of LC is dose-response, that is, the number of 
cigarettes per day and the duration of smoking, sig-
nificantly increases the risk of LC37. 
AflAtoxin 
Food contamination with aflatoxin is one of the 
major risk factors for hepatocellular carcinoma 
(HCC)39,40. Aflatoxin is a toxic and carcinogenic 
chemical produced by Aspergillus fungus and it 
contaminates food products such as maize, peanuts 
and nuts41,42. The highest level of exposure to this 
risk factor belongs to Sub-Saharan Africa and East 
Asia especially South China41,43. In areas with high 
exposure to aflatoxin, it has multiplying interaction 
with HBV, and thus the presence of these two fac-
tors together increases the risk of HCC in an expo-
nential fashion44. 
DietAry fActors
Evidence suggests that the dietary composition plays 
an important role in the risk of developing HCC and 
may act as a protective agent. Compared to other 
types of cancer, there are few studies on the role of 
diet supplement in development of HCC45. Reporting 
data indicates that the high consumption of red meat 
and sugar has a positive relationship with susceptibili-
ty to HCC, but the high consumption of white meat or 
fish46,47, vegetables48,49, fruits50, cereals, eggs51, milk50 
and yogurt48 has reverse relationship with HCC.  An 
increase of 100 g of daily intake of vegetables reduc-
es the risk of HCC by 8%, and the consumption of 
20 g of fish instead of red meat per day reduced its 
risk by 16%52,53. However, some other studies54-56 did 
not indicate any significant relationship between the 
consumption of fruits and the risk of LC. Coffee con-
sumption also has a reverse relationship with suscep-
tibility to LC as the coffee contains various types of 
chemicals such as antioxidants, minerals and many 
phenolic compounds that have favorable potential ef-
fects on the liver and reduce the risk of LC57-60. The 
results of a meta-analysis in 2012 indicated that the 
RR of LC was 0.66 in people who consumed coffee, 
compared to those who didn’t61. 
non-Alcoholic fAtty liver DiseAse (nAflD)
Non-alcoholic fatty liver disease (NAFLD) with an 
estimated prevalence of 25.2% is one of the most 
common chronic liver diseases worldwide62. It may 
progress to non-alcoholic steatohepatitis (NASH), 
cirrhosis, and hepatocellular carcinoma (HCC)62. 
Recent data indicate that this disease is the lead-
ing cause of HCC63-65, so that the number of HCC 
cases related to the NAFLD had 9% of increase in 
the United States from 2004 to 200963, and the inci-
dence of HCC was reported equal to 44 per 100000 
people per year among patients with NAFLD62. 
changes were probably due to changes in the risk 
factors for this cancer in different regions24. For in-
stance, an increase in the prevalence of overweight, 
obesity, and diabetes may play an important role in 
the recent unfavorable trend in some regions espe-
cially North America25. 
RISK FACTORS FOR LC
hepAtitis B (hBv) AnD hepAtitis c (hcv)
viruses
Chronic infections with HBV and HCV are the main 
causes of HCC worldwide26,27 accounting for three 
quarters of all cases of LC worldwide28. HBV in 
East Asia and HCV in the Mediterranean countries 
are more observable29. There is a strong geograph-
ical correlation between the incidence of chronic 
infection with HBV and the incidence of HCC. It 
is estimated that 54% of LCs can be attributed to 
infection of HBV30. Despite the fact that most LC 
cases associated with HBV occur in low and mid-
dle-income countries29, the estimated risk of devel-
oping HCC among patients infected by HCV com-
pared to uninfected ones ranges between 20 and 30 
in most epidemiological studies25. However, studies 
carried out in the United States also indicated the 
association between the LC and HBV30. In addition, 
about 33% of LC was due to HCV worldwide. This 
rate was higher in low and middle-income countries 
than the high-income countries31.                        
Alcohol Drinking
Results of previous studies showed that heavy 
drinking increases the incidence of primary LC32,33. 
More than one daily drinking in women and twice 
a day in men are usually considered as the high al-
cohol consumption32, so that the Relative Risk (RR) 
of LC in people who drink 3 times or more alcohol 
per day is 1.16 and the RR for those who consume 
6 times or more alcohol per day is 1.22 higher than 
those who do not drink alcohol34. A prospective Co-
hort study in 8 European countries also attributed 
33% and 18% of LC cases to the past and current 
history of alcohol consumption35. 
cigArette AnD toBAcco
Many studies have reported a significant association 
between cigarette and tobacco smoking with LC. It 
has been found that the relative risk of LC is high-
er in people who are currently smoking than those 
who have a history of smoking36,37. A meta-analysis 
investigation on this field, which included 38 cohort 
studies and 58 case-control studies, revealed a rel-
ative risk of LC equal to 1.51 and 1.12 in current 
smokers and those with a history of smoking com-
pared to those who never smoked38. Interestingly, 
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general, the risk of LC in those with a familial history 
is twice more than those without the familial history93. 
Age AnD sex
In most high-risk areas, the incidence of this cancer 
increases after the age of 20 and peaks at the age of 
50 and above. In these areas, the incidence of LC 
may be also seen before the age of 20. The second 
model can be seen in low-risk areas where the inci-
dence of LC steadily increases by age. Its incidence 
rises after the age of 45 to 50, and becomes almost 
constant after 65. LC is usually 2 to 4 times higher 
in men than women94,95 due to the more exposure of 
men to important risk factors of this cancer such as 
alcohol, smoking, and the infected injection96. 
socioeconomic stAtus
Studies have found that the incidence and mortality of 
LC have different models in countries with multitude 
geographical, cultural, social and economic back-
grounds97, so that more LC cases are annually diagnosed 
in less developed countries, since people who are living 
in lower socioeconomic areas are more exposed to risk 
factors such as HBV, alcohol and tobacco consumption 
and their access to health systems is lower, thus making 
higher the incidence and mortality of LC98-102. 
CONCLUSIONS
The present study aimed to investigate the incidence 
and mortality of LC in the world and the associa-
tion between different risk factors of LC. Findings 
of the present study indicated that the ASIR of LC 
was 10.1 per 100,000 people and the ASMR for LC 
was 9.5 per 100,000 people worldwide. The most 
important risk factors of LC included the chronic 
infections with HBV and HCV, aflatoxin, alcohol 
drinking and smoking. Excessive consumption of 
white meat or fish, vegetables, fruits, cereals, eggs, 
milk and yogurt was known as a protective agent for 
this cancer. However, this is not a systematic review 
and only English studies were included.
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